Search

Your search keyword '"Tobias Huebner"' showing total 4 results
Start Over Author "Tobias Huebner"
4 results on '"Tobias Huebner"'

1. Geheimakte Computer : Everything they don’t teach you about tech

Author

Tobias Hübner and Tobias Hübner

Subjects
Computer science, Computers
Abstract

Der Informatikunterricht ist dir zu trocken? Du bist auf der Suche nach den wirklich spannenden Themen? Halt! Psssst! Dann wirf doch einen Blick in die „Geheimakte Computer“. Sie ist dein Einstieg in die große weite IT-Welt. Hier erfährst du alles, was dich rund um den Computer wirklich interessiert: Bastelprojekte, Computerspiele, Programmierung und nützliches Wissen zu spannenden Themen wie Hacking, Digitalisierung und Sicherheit, künstliche Intelligenz und interessante Persönlichkeiten der Branche.Aus dem Inhalt:Der Computer: das kreativste Werkzeug der WeltKomplex, aber im Prinzip einfach: So funktioniert ein ComputerAlte Technik neu entdeckenGames – besser als ihr RufEine Spielkonsole mit dem Raspberry PiDie dunkle Seite: Hacker-Tricks und wie man sich davor schütztWie gefährlich ist KI?Digitalisierung: Propheten gegen ApokalyptikerDie fiesen Tricks der Tech-IndustrieVision: Die Zukunft des Computers

Published
2023

2. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Author

Pedro David Wendel Garcia, Thierry Fumeaux, Philippe Guerci, Dorothea Monika Heuberger, Jonathan Montomoli, Ferran Roche-Campo, Reto Andreas Schuepbach, Matthias Peter Hilty, Mario Alfaro Farias, Antoni Margarit, Gerardo Vizmanos-Lamotte, Thomas Tschoellitsch, Jens Meier, Francesco S. Cardona, Josef Skola, Lenka Horakova, Hernan Aguirre-Bermeo, Janina Apolo, Emmanuel Novy, Marie-Reine Losser, Geoffrey Jurkolow, Gauthier Delahaye, Sascha David, Tobias Welte, Tobias Wengenmayer, Dawid L. Staudacher, Theodoros Aslanidis, Barna Babik, Anita Korsos, Janos Gal, Hermann Csaba, Abele Donati, Andrea Carsetti, Fabrizio Turrini, Maria Sole Simonini, Roberto Ceriani, Martina Murrone, Emanuele Rezoagli, Giovanni Vitale, Alberto Fogagnolo, Savino Spadaro, Maddalena Alessandra Wu, Chiara Cogliati, Riccardo Colombo, Emanuele Catena, Francesca Facondini, Antonella Potalivo, Gianfilippo Gangitano, Tiziana Perin, Maria Grazia Bocci, Massimo Antonelli, Diederik Gommers, Can Ince, Eric Mayor-Vázquez, Maria Cruz, Martin Delgado, Raquel Rodriguez Garcia, Jorge Gamez Zapata, Begoña Zalba-Etayo, Herminia Lozano-Gomez, Pedro Castro, Adrian Tellez, Adriana Jacas, Guido Muñoz, Rut Andrea, Jose Ortiz, Eduard Quintana, Irene Rovira, Enric Reverter, Javier Fernandez, Miquel Ferrer, Joan R. Badia, Arantxa Lander Azcona, Jesus Escos Orta, Philipp Bühler, Silvio Brugger, Daniel Hofmaenner, Simone Unseld, Frank Ruschitzka, Mallory Moret-Bochatay, Bernd Yuen, Thomas Hillermann, Hatem Ksouri, Govind Oliver Sridharan, Anette Ristic, Michael Sepulcri, Miodrag Filipovic, Urs Pietsch, Petra Salomon, Iris Drvaric, Peter Schott, Severin Urech, Adriana Lambert, Lukas Merki, Marcus Laube, Frank Hillgaertner, Marianne Sieber, Alexander Dullenkopf, Lina Petersen, Serge Grazioli, Peter C. Rimensberger, Isabelle Fleisch, Jerome Lavanchy, Katharina Marquardt, Karim Shaikh, Hermann Redecker, Michael Stephan, Jan Brem, Bjarte Rogdo, Andre Birkenmaier, Friederike Meyer zu Bentrup, Patricia Fodor, Pascal Locher, Giovanni Camen, Martin Siegemund, Nuria Zellweger, Marie-Madlen Jeitziner, Beatrice Jenni-Moser, Christian Bürkle, Gian-Reto Kleger, Marilene Franchitti Laurent, Jean-Christophe Laurent, Tomislav Gaspert, Marija Jovic, Michael Studhalter, Christoph Haberthuer, Roger F. Lussman, Daniela Selz, Didier Naon, Romano Mauri, Samuele Ceruti, Julien Marrel, Mirko Brenni, Rolf Ensner, Nadine Gehring, Antje Heise, Tobias Huebner, Thomas A. Neff, Sara Cereghetti, Filippo Boroli, Jerome Pugin, Nandor Marczin, Joyce Wong, University of Zurich, Wendel Garcia, Pedro David, RISC-19 ICU investigators, Graduate School, Translational Physiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, Intensive Care, Grazioli, Serge, and Rimensberger, Peter

Subjects
medicine.medical_specialty, ARDS, medicine.medical_treatment, 610 Medicine & health, Disease, 2700 General Medicine, 01 natural sciences, Article, NO, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, Medicine, 030212 general & internal medicine, 0101 mathematics, Disease burden, Mechanical ventilation, lcsh:R5-920, Public health, ddc:618, Acute respiratory distress syndrome, Pandemic, business.industry, Incidence (epidemiology), 010102 general mathematics, COVID-19, General Medicine, medicine.disease, Intensive care unit, Coronavirus, Cohort, Absolute neutrophil count, 10209 Clinic for Cardiology, 10023 Institute of Intensive Care Medicine, lcsh:Medicine (General), business
Abstract

Background Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. Methods Following the critical developments in ICUs in regions experiencing early inception of the pandemic, the European-based, international RIsk Stratification in COVID-19 patients in the Intensive Care Unit (RISC-19-ICU) registry was created to provide near real-time assessment of patients developing critical illness due to COVID-19. Findings As of April 22, 2020, 639 critically ill patients with confirmed SARS-CoV-2 infection were included in the RISC-19-ICU registry. Of these, 398 had deceased or been discharged from the ICU. ICU-mortality was 24%, median length of stay 12 (IQR, 5-21) days. ARDS was diagnosed in 74%, with a minimum P/F-ratio of 110 (IQR, 80-148). Prone positioning, ECCO2R, or ECMO were applied in 57%. Off-label therapies were prescribed in 265 (67%) patients, and 89% of all bloodstream infections were observed in this subgroup (n = 66; RR=3·2, 95% CI [1·7-6·0]). While PCT and IL-6 levels remained similar in ICU survivors and non-survivors throughout the ICU stay (p = 0·35, 0·34), CRP, creatinine, troponin, d-dimer, lactate, neutrophil count, P/F-ratio diverged within the first seven days (p

Published
2020

3. Analgesic efficacy of equimolar 50% nitrous oxide/oxygen gas premix (Kalinox®) as compared with a 5% eutectic mixture of lidocaine/prilocaine (EMLA®) in chronic leg ulcer debridement

Author

Stefan Arndt, Ulrike Held, Thomas A Neff, Tobias Huebner, Maria Signer, and Juerg Traber

Subjects
medicine.medical_specialty, Debridement, Lidocaine/prilocaine, Inhalation, Lidocaine, business.industry, Visual analogue scale, medicine.medical_treatment, Analgesic, Dermatology, Crossover study, Prilocaine, Surgery, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Anesthesia, medicine, 030212 general & internal medicine, business, medicine.drug
Abstract

Chronic foot and leg ulcers are a common health problem worldwide. A mainstay of chronic ulcer therapy is sharp mechanical wound debridement requiring potent analgesia. In this prospective, controlled, single-centre, crossover design study, patients were assigned to either the administration of topical analgesia with 5% lidocaine/prilocaine cream or the inhalation of an analgesic 50% N2 O/O2 gas premix. Primary outcome parameter was level of pain at maximum wound depth during debridement as measured by a visual analogue scale. Secondary outcomes included level of pain after debridement, overall duration of treatment session, duration and completeness of debridement, and the patient's subjective perception of analgesic quality during debridement. Pain level increased from 0·60/0·94 (first/second debridement; baseline) to 1·76/2·50 (debridement) with 5% lidocaine/prilocaine and from 1·00/1·35 (baseline) to 3·95/3·29 (debridement) with 50% N2 O/O2 gas premix. Patient satisfaction was 90·48%/94·44% (first/second debridement) with topical 5% lidocaine/prilocaine analgesia and 90·48%/76·47% with the inhalation of 50% N2 O/O2 gas premix. Debridement was completed in a significantly higher percentage of 85·71%/88·89% (first/second debridement) with 5% lidocaine/prilocaine than with 50% N2 O/O2 gas premix (42·86%/58·82%) (odds ratio 6·7; P = 0·001). This study provides sound evidence that analgesia with topically administered 5% lidocaine/prilocaine cream is superior to the use of inhaled 50% N2 O/O2 gas premix in chronic leg ulcer debridement.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results